These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 25456366)

  • 21. Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy.
    Carrion A; Ingelmo-Torres M; Lozano JJ; Montalbo R; D'Anna M; Mercader C; Velez E; Ribal MJ; Alcaraz A; Mengual L
    Urol Oncol; 2021 Aug; 39(8):493.e17-493.e25. PubMed ID: 33189527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.
    Chan TY; Partin AW; Walsh PC; Epstein JI
    Urology; 2000 Nov; 56(5):823-7. PubMed ID: 11068310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
    Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
    Shukla S; Zhang X; Niknafs YS; Xiao L; Mehra R; Cieślik M; Ross A; Schaeffer E; Malik B; Guo S; Freier SM; Bui HH; Siddiqui J; Jing X; Cao X; Dhanasekaran SM; Feng FY; Chinnaiyan AM; Malik R
    Neoplasia; 2016 Aug; 18(8):489-99. PubMed ID: 27566105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.
    Secin FP; Bianco FJ; Vickers AJ; Reuter V; Wheeler T; Fearn PA; Eastham JA; Scardino PT
    Cancer; 2006 Jun; 106(11):2369-75. PubMed ID: 16649221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
    Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
    Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.
    Zhao SG; Chang SL; Spratt DE; Erho N; Yu M; Ashab HA; Alshalalfa M; Speers C; Tomlins SA; Davicioni E; Dicker AP; Carroll PR; Cooperberg MR; Freedland SJ; Karnes RJ; Ross AE; Schaeffer EM; Den RB; Nguyen PL; Feng FY
    Lancet Oncol; 2016 Nov; 17(11):1612-1620. PubMed ID: 27743920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
    Corradi JP; Cumarasamy CW; Staff I; Tortora J; Salner A; McLaughlin T; Wagner J
    Prostate; 2021 Jul; 81(10):694-702. PubMed ID: 34002865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.
    Lo Iacono M; Buttigliero C; Monica V; Bollito E; Garrou D; Cappia S; Rapa I; Vignani F; Bertaglia V; Fiori C; Papotti M; Volante M; Scagliotti GV; Porpiglia F; Tucci M
    Oncotarget; 2016 Mar; 7(12):14394-404. PubMed ID: 26887047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database.
    Freedland SJ; Aronson W; Presti JC; Kane CJ; Terris MK; Elashoff D; Amling CL;
    J Urol; 2003 Jun; 169(6):2142-6. PubMed ID: 12771736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
    Hegde JV; Veruttipong D; Said JW; Reiter RE; Steinberg ML; King CR; Kishan AU
    Urology; 2017 Sep; 107():171-177. PubMed ID: 28552819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
    Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
    Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.